Citadel Advisors
ECYT

Citadel Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Citadel Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,700
Closed -$900K – 10202
2018
Q3 		$900K Buy
50,700
+17,500
+53% +$300K ﹤0.01% 5730
2018
Q2 		$458K Buy
33,200
+21,700
+189% +$258K ﹤0.01% 6517
2018
Q1 		$105K Buy
+11,500
New +$63.4K ﹤0.01% 7693
2016
Q3 		– Sell
-13,700
Closed -$44K – 8086
2016
Q2 		$44K Sell
13,700
-2,100
-13% -$7.7K ﹤0.01% 6441
2016
Q1 		$49K Sell
15,800
-12,500
-44% -$40.8K ﹤0.01% 6257
2015
Q4 		$113K Buy
28,300
+12,700
+81% +$58.5K ﹤0.01% 6560
2015
Q3 		$71K Buy
15,600
+3,900
+33% +$20.4K ﹤0.01% 7292
2015
Q2 		$61K Sell
11,700
-10,000
-46% -$60K ﹤0.01% 7527
2015
Q1 		$136K Sell
21,700
-32,900
-60% -$190K ﹤0.01% 6588
2014
Q4 		$343K Sell
54,600
-9,300
-15% -$56.7K ﹤0.01% 5240
2014
Q3 		$389K Sell
63,900
-24,300
-28% -$166K ﹤0.01% 4951
2014
Q2 		$581K Buy
88,200
+56,800
+181% +$640K ﹤0.01% 4194
2014
Q1 		$748K Buy
31,400
+26,500
+541% +$384K ﹤0.01% 3802
2013
Q4 		$52K Buy
+4,900
New +$54.1K ﹤0.01% 6017

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Citadel Advisors's ECYT Position: Q4 2018 in Review

Citadel Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,361,949 shares — an estimated $24.2M sold.

Citadel Advisors first reported a position in ECYT in Q4 2013 and held it in 18 quarters. The position peaked at $27.6M in Q2 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Citadel Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Citadel Advisors sold 1,361,949 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $24.2M.
  • Citadel Advisors first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 18 quarters.
  • Citadel Advisors's Endocyte, Inc. Common Stock position peaked at $27.6M in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.